LXE408 is an oral antileishmanarial compound that selectively targets the kinetoplastid proteosome vs. the mammalian proteosome. The prior candidate, GNF6702, had solubility-limited oral absorption, which could have been addressed with…
Drug Hunter > Molecules > LXE408
become a member to continue reading
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.
- Stay up-to-date and save more time with exclusive members-only content
- On-board new team members with educational content and case studies
- Generate ideas and discussion with easy-to-read slide decks
- Generate ideas and discussion with easy-to-read slide decks